DexCom, Inc. Share Price Wiener Boerse
Equities
DXCM
US2521311074
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.2 EUR | -2.69% | -7.26% | -2.87% |
05-30 | Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target | MT |
05-24 | Declaration of Voting Results by DexCom, Inc | CI |
Sales 2024 * | 4.33B 3.98B 339B | Sales 2025 * | 5.15B 4.73B 403B | Capitalization | 47.23B 43.38B 3,694B |
---|---|---|---|---|---|
Net income 2024 * | 732M 672M 57.25B | Net income 2025 * | 910M 836M 71.17B | EV / Sales 2024 * | 11.2 x |
Net Debt 2024 * | 1.43B 1.32B 112B | Net Debt 2025 * | 994M 913M 77.75B | EV / Sales 2025 * | 9.36 x |
P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
53.7
x | Employees | 9,550 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on DexCom, Inc.
1 day | -2.69% | ||
1 week | -7.26% | ||
1 month | -6.99% | ||
3 months | -0.33% | ||
6 months | +1.70% | ||
Current year | -2.87% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 31/10/07 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 31/08/18 |
Chief Tech/Sci/R&D Officer | 47 | 30/09/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 19/11/09 |
Mark Foletta
BRD | Director/Board Member | 63 | 18/11/14 |
Eric Topol
BRD | Director/Board Member | 69 | 08/07/09 |
Date | Price | Change |
---|---|---|
30/05/24 | 109.1 | -6.53% |
30/05/24 | 116.8 | -1.85% |
29/05/24 | 119 | +2.09% |
28/05/24 | 116.5 | -0.12% |
27/05/24 | 116.7 | -0.87% |
End-of-day quote Wiener Boerse, May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.41% | 178B | |
-0.91% | 107B | |
-2.18% | 67.04B | |
+11.73% | 44.62B | |
+9.25% | 42.5B | |
+14.60% | 29.99B | |
+15.97% | 25.22B | |
-6.51% | 24.14B | |
-6.27% | 23.69B |
- Stock Market
- Equities
- DXCM Stock
- DXCM Stock